Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Atherosclerotic cardiovascular disease (ASCVD) is a chronic condition characterized by the buildup of cholesterol-rich plaques within arterial walls, leading to complications such as coronary artery disease, stroke, and peripheral artery disease. According to the Office of Health Economics, ASCVD contributes to approximately 261 million disability-adjusted life years (DALYs) globally each year, highlighting its substantial health burden. As per the atherosclerotic cardiovascular disease (ASCVD) pipeline analysis by Expert Market Research, the pipeline is advancing through the development of lipid-lowering therapies, anti-inflammatory agents, PCSK9 inhibitors, RNA-based therapeutics, and gene-targeted treatments. The growing emphasis on early cardiovascular risk reduction, precision medicine, and innovative biologics is expected to accelerate ASCVD pipeline growth and expand future treatment options.
-
Major companies involved in atherosclerotic cardiovascular disease (ASCVD) pipeline analysis include AstraZeneca, Beijing Inno Medicine Co., Ltd., Kylonova (Xiamen) Biopharma co., Ltd, and others.
-
Leading drugs currently in the pipeline include AZD0780, YN001, Kylo-11, and others.
-
The ASCVD treatment landscape is advancing through PCSK9 inhibitors, RNA-based therapeutics, and anti-inflammatory therapies, while increasing emphasis on lipid management, cardiovascular risk reduction, and targeted drug development is expected to strengthen pipeline expansion and clinical innovation in the coming years.
Report Coverage
The Atherosclerotic Cardiovascular Disease (ASCVD) Pipeline Analysis Report by Expert Market Research gives comprehensive insights into atherosclerotic cardiovascular disease (ASCVD) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for atherosclerotic cardiovascular disease (ASCVD). The atherosclerotic cardiovascular disease (ASCVD) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The atherosclerotic cardiovascular disease (ASCVD) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with atherosclerotic cardiovascular disease (ASCVD) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to atherosclerotic cardiovascular disease (ASCVD).
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Atherosclerotic Cardiovascular Disease (ASCVD) Pipeline Outlook
Atherosclerotic cardiovascular disease (ASCVD) is a chronic cardiovascular disorder characterized by the buildup of cholesterol-rich plaques within arterial walls. This process, known as atherosclerosis, causes arterial narrowing, reduced blood flow, and vascular inflammation. Plaque progression or rupture can trigger serious complications, including coronary artery disease, myocardial infarction, ischemic stroke, and peripheral artery disease.
Atherosclerotic cardiovascular disease (ASCVD) treatment focuses on reducing cardiovascular risk, slowing plaque progression, and preventing adverse cardiac events. Standard therapies include statins, antiplatelet agents, antihypertensive medications, and lipid-lowering drugs. Emerging therapies target vascular inflammation and residual inflammatory risk to improve long-term cardiovascular outcomes. In June 2023, AGEPHA Pharma received United States Food and Drug Administration approval for LODOCO (colchicine), the first anti-inflammatory cardiovascular therapy indicated for adults with established Atherosclerotic Cardiovascular Disease (ASCVD). The therapy demonstrated a significant reduction in myocardial infarction, stroke, coronary revascularization, and cardiovascular death risk, strengthening the ASCVD pipeline and advancing cardiovascular disease treatment strategies.
Atherosclerotic Cardiovascular Disease (ASCVD) Epidemiology
The pipeline is gaining increasing importance as the global burden of atherosclerotic cardiovascular disease, ischemic heart disease, and related vascular disorders continues to rise. According to the Office of Health Economics, ASCVD accounts for approximately 261 million disability-adjusted life years (DALYs) worldwide annually, highlighting its significant health impact. Furthermore, as per Ziyi Li et al. (2024), the prevalence of ischemic heart disease among individuals aged 20–54 years increased by 20.55% between 1990 and 2019. The rising incidence of ASCVD, particularly among younger populations and in lower socio-demographic regions, is driving demand for innovative cardiovascular therapeutics, supporting advancements in the ASCVD pipeline and future treatment development.
Atherosclerotic Cardiovascular Disease (ASCVD) – Pipeline Therapeutic Assessment
This section of the report covers the analysis of atherosclerotic cardiovascular disease (ASCVD) drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase 1)
- Preclinical and Discovery Stage Products
By Drug Class
The atherosclerotic cardiovascular disease (ASCVD) pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Peptides
- Polymers
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Atherosclerotic Cardiovascular Disease (ASCVD) Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total atherosclerotic cardiovascular disease (ASCVD) clinical trials, accounting for around 32%, reflecting strong late-stage development potential and supporting future commercialization. Phase IV with 26%highlights continued post-marketing expansion and evidence generation. Phase II at 25% demonstrates a robust innovation base, while phase I with 11% and early phase with 6% indicate a steady flow of emerging candidates that can strengthen long-term market growth.
Atherosclerotic Cardiovascular Disease (ASCVD) Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the atherosclerotic cardiovascular disease (ASCVD) pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The atherosclerotic cardiovascular disease (ASCVD) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for atherosclerotic cardiovascular disease (ASCVD). Lipid-lowering therapies remain a key focus area in the pipeline, aiming to achieve superior low-density lipoprotein cholesterol (LDL-C) reduction and improved cardiovascular risk management. For instance, AZD0780, an oral Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitor, is currently under Phase III evaluation for patients with clinical ASCVD or those at risk of a first ASCVD event. The therapy is designed to significantly lower LDL-C levels, supporting advances in ASCVD treatment, cholesterol management, and cardiovascular disease prevention.
Atherosclerotic Cardiovascular Disease (ASCVD) Clinical Trials – Key Players
The EMR report for the atherosclerotic cardiovascular disease (ASCVD) pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed atherosclerotic cardiovascular disease (ASCVD) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in atherosclerotic cardiovascular disease (ASCVD) clinical trials:
- AstraZeneca
- Beijing Inno Medicine Co., Ltd.
- Kylonova (Xiamen) Biopharma co., Ltd.
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Hudson Biotech
- Cyclarity Therapeutics, Inc.
- Amgen
- Novartis Pharmaceuticals
- Eli Lilly and Company
- Genentech, Inc.
- CSL Behring
Atherosclerotic Cardiovascular Disease (ASCVD) – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for atherosclerotic cardiovascular disease (ASCVD). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of atherosclerotic cardiovascular disease (ASCVD) drug candidates.
Drug: AZD0780
AZD0780, sponsored by AstraZeneca, is currently being evaluated in the Phase III AZURE-LDL study for patients with clinical ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) or those at risk of experiencing a first ASCVD event. AZD0780 is a novel, once-daily oral small-molecule PCSK9 inhibitor designed to lower low-density lipoprotein cholesterol (LDL-C) by inhibiting PCSK9 signaling, thereby enhancing LDL-C clearance from the bloodstream. The primary objective of this randomized, double-blind, placebo-controlled trial is to evaluate the efficacy, safety, and tolerability of AZD0780 in reducing LDL-C levels when administered in combination with high-intensity lipid-lowering therapy. The study is enrolling approximately 3,100 participants across multiple countries and is expected to be completed in January 2027.
Drug: YN001
YN001 is being evaluated in a randomized, double-blind, placebo-controlled Phase IIa clinical trial sponsored by Beijing Inno Medicine Co., Ltd. The study is examining the efficacy and safety of YN001 in patients with Atherosclerotic Cardiovascular Disease (ASCVD), cerebrovascular disease, and erectile dysfunction. YN001 is a first-in-class investigational targeted liposomal therapy administered as a 20 mg dose with 5% glucose injection. The drug is designed to actively target atherosclerotic lesions, delivering its therapeutic agent directly to plaques to promote plaque regression, reduce plaque volume, and enhance plaque stability. The trial is expected to begin in January 2026, with primary completion anticipated in June 2026 and overall study completion projected for November 2026.
Drug: Kylo-11
Kylo-11 is an investigational LPA-targeted small interfering RNA (siRNA) therapy being sponsored by Kylonova (Xiamen) Biopharma Co., Ltd. for the treatment of atherosclerotic cardiovascular disease (ASCVD) in patients with elevated lipoprotein(a) [Lp(a)] levels. Administered through subcutaneous injection, the drug utilizes an advanced dual-conjugated siRNA delivery platform designed to silence the LPA gene, thereby reducing the production of Lp(a), a genetically driven cardiovascular risk factor associated with inflammation and atherosclerosis progression. The ongoing Phase II, randomized, double-blind, placebo-controlled, multicenter study is evaluating the efficacy, safety, and optimal dosing regimen of Kylo-11. The trial is expected to reach primary completion in February 2027, with overall study completion anticipated in August 2028.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Atherosclerotic Cardiovascular Disease (ASCVD) Pipeline Insight Report
- Which companies/institutions are leading atherosclerotic cardiovascular disease (ASCVD) drug development?
- Which company is leading the atherosclerotic cardiovascular disease (ASCVD) pipeline development activities?
- What is the current atherosclerotic cardiovascular disease (ASCVD) commercial assessment?
- What are the opportunities and challenges present in the atherosclerotic cardiovascular disease (ASCVD) pipeline landscape?
- What is the efficacy and safety profile of atherosclerotic cardiovascular disease (ASCVD) pipeline drugs?
- Which company is conducting major trials for atherosclerotic cardiovascular disease (ASCVD) drugs?
- Which companies/institutions are involved in atherosclerotic cardiovascular disease (ASCVD) collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in Atherosclerotic cardiovascular disease (ASCVD)?
Reasons To Buy This Report
The Atherosclerotic Cardiovascular Disease (ASCVD) Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for atherosclerotic cardiovascular disease (ASCVD). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into atherosclerotic cardiovascular disease (ASCVD) collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Atherosclerotic Cardiovascular Disease Epidemiology Forecast
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
